drugset / Trial / NCT01467700
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of Ramelteon, once daily (QD), sublingual (SL), in adult participants with acute depressive episodes associated with Bipolar I disorder.
Timeline
- Start
- 2011-12
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ramelteon | Unknown | 0.1 mg | Subcutaneous |
| Subject | Ramelteon | Unknown | 0.4 mg | Subcutaneous |
| Subject | Ramelteon | Unknown | 0.8 mg | Subcutaneous |